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 Enhanced S-cone syndrome (ESCS) is an autosomal re-
cessive retinopathy characterized by a gain of visual function:
Patients with ESCS exhibit electroretinogram (ERG) responses
to short wavelength stimulation 30 times higher in amplitude
than normal corresponding to S-cone function. This disease
also includes night blindness and similar photopic and scotopic
ERGs [1,2]. Histological data from one elderly patient with
advanced disease showed an absence of rods but a two-fold
increase in the cone population, 92% of which were thought
to be S-cones, while in vivo examination of early disease has
shown an abnormal retinal architecture [3,4]. These histologi-
cal findings would explain the gain of function observed in
ESCS patients. ESCS could therefore be considered as a de-
velopmental defect, which results in an increase in photore-
ceptor cells taking an S-cone fate [5].
Identification of mutations in the NR2E3 gene, encoding
an orphan nuclear receptor transcription factor, has paved the
way to our current understanding of the disease [6,7]. The ex-
pression of NR2E3 is restricted to rod photoreceptors in hu-
man, although the disease is characterized by an increase in
S-cone function [7-9].
Studies of rd7 mouse retinas, a murine model with a ho-
mozygous insertion of a L1 retrotransposon into exon 5 of
Nr2e3 gene, have also revealed a two fold increase in S-cone
number, retinal dystrophy at early stages and slow retinal de-
generation [10-12]. Expression of NR2E3 in mouse retina is
restricted to rod nuclei, starts after the completion of cone cell
birth, and peaks after completion of rod cell differentiation
[13,14].
The current hypothesis is that NR2E3 represses S-cone
fate as well as participates in rod photoreceptor commitment
[5,13-17]. The intrinsic genetic program appears to be the
major determinant of cell-fate commitment in the retina [18].
The competence model of cell-fate determination proposes that
a homogeneous pool of multipotent progenitors passes through
states of competence where it can produce a given set of cell
types [19]. Transcription factors are among the best charac-
terized intrinsic factors, and NR2E3 may have a similar role
as its paralog NR2E1 in driving pluripotent cells to a particu-
lar fate [20].
NR2E3, as a nuclear receptor, possesses a central DNA
binding domain (DBD), and a C-terminal ligand binding do-
main (LBD) [21]; it was originally described as a transcrip-
tional repressor and binds DNA as a homodimer [14,22]. Physi-
cal and functional interactions of NR2E3 with several tran-
scription factors involved in photoreceptor differentiation have
been established [14,23]. It has recently been shown that
NR2E3 directly interacts with the nuclear receptor NR1D1
and the homeoprotein Crx [14,23]. These interactions lead to
enhanced expression of rod-specific genes and reduced ex-
pression of cone-specific genes in vitro. NR2E3 also interacts
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with Nrl, a photoreceptor specific transcription factor, and
modulates its transcriptional activity [15]. The absence of func-
tional Nrl gene in mouse gives a severe phenotype with a com-
plete loss of rods replaced by S-cones. Interestingly, the ex-
pression of NR2E3 has been shown to be dependent upon Nrl,
suggesting that the increase in S-cones in the Nrl-/- mouse
results in part from the absence of expression of NR2E3 [16].
Analysis of gene expression modification in rd7 mouse
retina has been performed using different approaches
[14,15,17]. Microarray analyses revealed an up-regulation of
numerous cone-specific genes in rd7 mouse retina, pointing
out NR2E3 repressive function [14,17], while chromatin im-
munoprecipitation assays associated with reverse transcriptase
polymerase chain reaction (RT-PCR) analysis, demonstrated
that NR2E3 represses cone specific genes but activates the
expression of rod-specific genes [15]. In addition, the
transcriptome of the retina of transgenic mice overexpressing
NR2E3 confirms the role of NR2E3 as a suppressor of the
expression of cone-specific genes [24]. Corbo and Cepko also
reported a delay of rhodopsin expression in rd7 mouse [17].
In rat, during development, there is about a week-long period
between birth of rods and onset of rhodopsin expression [25].
During this period, NR2E3 would suppress S-cone fate by
reducing S-cone gene expression as well as promoting rod
fate by activating rod-specific promoters [14,15,23,24].
In the present paper, we analyzed the transcriptional prop-
erties of the LBD of NR2E3 (from residue 113 to 410) mu-
tants found in ESCS, fused to a heterologous DBD (Gal4DBD),
to circumvent a problem due to DNA binding specificity [26],
as well as the full length protein to get a better understanding
of the activity of NR2E3 mutants in a more physiological con-
text [14].
We confirmed that NR2E3 inhibitory properties involve
the helix H12 of the LBD as observed for other nuclear recep-
tors [14,27]. We reported an absence of correlation between
transcriptional inhibitory properties of NR2E3LBD and ESCS,
implying the existence of some transcriptional activation prop-
erties that might be controlled by a yet to be identified ligand
[28].
METHODS
Transfection assays in COS-1 and HeLa cells:  Transfections
were performed in COS-1 and HeLa cells, which were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Cergy-Pontoise, France) supplemented with 10% fetal
bovine serum (Gibco).
COS-1 cells were transiently transfected by the calcium
phosphate precipitate method [29]: Cells were plated at a den-
sity of 3.5X 105 cells/ml in 24-well tissue culture plates (500
µl/well) and incubated for 2 h at 37 °C in a humidified 5%
CO2 incubator before transfection. Cells were transfected with
500 ng of Gal4 or NR2E3 responsive luciferase reporter con-
struct [14], 10 ng of pRL-TK internal reporter construct
(Promega, Charbonnieres, France) and a variable amount of
different expression constructs. One day after transfection, cells
were washed with medium without serum and changed to fresh
medium. Two days after transfection, lysates were collected
and luciferase activity was measured using the Dual Luciferase
Reporter Assay System (Promega).
HeLa cells were transfected using Lipofectamine 2000
reagent (Gibco-BRL). Cells were plated in six-well tissue cul-
ture plates (2 µl/well) and left until they reached 80%
confluence. Before transfection, cells were washed and
changed to OPTI-MEM medium (Gibco-BRL). Cells were
transfected with 750 ng of Gal4-responsive luciferase reporter
construct, 10 ng of pRL-TK internal reporter construct, a vari-
able amount of different expression constructs and 2.5 µl of
Lipofectamine 2000 according to the manufacturer’s instruc-
tions. Two days after transfection, lysates were collected and
luciferase activity was measured using the Dual Luciferase
Reporter Assay System. All transfection assays were performed
in triplicate. Each assay group was repeated at least twice.
Site-directed mutagenesis:  Point mutations were intro-
duced in NR2E3LBD from pCMV-Gal4-NR2E3LBD and pCMX-
HA-NR2E3 constructs obtained from Dr. Mime Kobayashi
[6]. Mutations were introduced by oligonucleotide-directed
mutagenesis using the thermostable Deep Vent DNA poly-
merase (New England Biolabs Inc., Beverly, MA). Amplified
DNA was digested by DpnI (New England Biolabs Inc.) and
used to transform XL-10 Gold ultra-competent E. coli cells
(Stratagene Europe, Hogehilweg, Netherlands). Mutations
were confirmed by sequencing.
Nuclear protein extraction:  Nuclear extracts were pre-
pared from transiently transfected COS-1 cells. Transfected
cells were rinsed with 1X PBS, harvested by centrifugation
for 5 min at 800x g at 4 °C, and washed with 5 volumes of
hypotonic buffer (10 mM HEPES, pH 7.5, 1X complete pro-
tease inhibitor cocktail [Boerhinger Mannheim, Mannheim,
Germany], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT). The
cells were suspended with 3 volumes of hypotonic buffer, and
incubated for 10 min on ice. Cytoplasmic membranes were
disrupted with a pestle B. Nuclei were harvested by centrifu-
gation for 15 min at 1,200x g, suspended with 0.5 volume of
low salt buffer (20 mM HEPES, pH 7.5, 1X Complete pro-
tease inhibitor cocktail, 2 mM KCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 25% glycerol) before the disruption of
nuclear membranes by drop-wise addition of 0.5 volume of
high salt buffer (20 mM HEPES, pH 7.5, 1X Complete pro-
tease inhibitor cocktail, 1.2 M KCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 25% glycerol). Nuclear lysates were
incubated 30 min on ice under agitation and harvested by cen-
trifugation for 30 min at 16,000x g at 4 °C. Supernatants were
aliquoted and stored at -80 °C until assayed.
NR2E3 protein binding assays:  NR2E3 protein binding
was detected by electrophoretic mobility shift assays. DNA
probes containing Gal4 (5'-GGG CCG ACG GGT GAC AGC
CCT CCG ACG GCC C-3') and Kni x2 binding site (5'-TAA
CCT TTT AAA AGT CAA AAG TCA ACT TCC AAC-3') [6]
were prepared by annealing complementary oligonucleotides
and labeled at both end with [α-32P]dCTP (6,000 Ci/mmol;
Amersham Biosciences, Saclay, France) by filling with the
large fragment of DNA polymerase I (Promega). Binding re-
actions contained 40,000 cpm of probe, 1 µg of double stranded
poly(dI-dC) (Amersham Biosciences), and 12.5 µg of bovine
595serum albumin in 50 µl of binding buffer (25 mM HEPES, pH
7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.1% NP40,
10% glycerol), with the nuclear protein fraction and competi-
tor oligonucleotide, 100 fold excess, as indicated. Reaction
mixtures were incubated 40 min at room temperature, and pro-
tein-DNA complexes were separated by electrophoresis on 4%
polyacrylamide gels in 0.5X Tris-borate-EDTA buffer at room
temperature. Radioactivity in gels was detected by autorad-
iography.
Western blot:  Nuclear extracts from transiently transfected
COS-1 cells were analyzed by Western-blot. Protein concen-
trations were estimated by Bradford’s technique. Proteins (10
µg/lane) were separated by 10% SDS-PAGE and transferred
onto nitrocellulose membrane (Schleicher and Schuell, Man-
tes-la-Ville, France), blocked with non-fat milk (5% w/v) and
incubated with the appropriated primary antibody overnight
at 4 °C. Gal4-NR2E3LBD fusion proteins were detected using
anti-Gal4DBD mouse monoclonal antibody (1/2,000, gift from
Pierre Chambon, Ph.D. France) while NR2E3 full length pro-
teins were detected using anti-HA-Tag mouse monoclonal an-
tibody (1/1,000, Cell Signaling Technology Inc., Danvers,
MA). The membrane was then washed, incubated with horse-
radish peroxidase labeled secondary antibody (1/15,000, Jack-
son ImmunoResearch Laboratories Inc., West Grove, PA), and
immunoreactive bands were detected by enhanced chemilu-
minescence (ECL+; Amersham, Biosciences).
RESULTS
Analysis of transcriptional repression by NR2E3LBD:  In order
to study the transcriptional properties of the LBD of NR2E3,
we expressed it as a chimeric protein, fused to the DBD of the
yeast transcription activator Gal4. This construct was tran-
siently transfected into COS-1 cells and tested on Gal4-re-
sponsive reporter plasmids using luciferase assay (Figure 1A).
First, to verify that the inhibitory properties of Gal4-NR2E3LBD
reported by others [14,22] were not due to specific elements
in the promoter, we performed experiments using Gal4 bind-
ing sites, upstream of two different minimal promoters; the β-
globin and the SV40 proximal promoter. In Figure 1A, tran-
scriptional inhibition mediated by Gal4-NR2E3LBD was dose-
dependent from 10-100 ng for both reporter constructs. This
inhibition is due to the NR2E3LBD, since the heterologous DBD
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Figure 1. Transcriptional repression
by NR2E3LBD.  COS-1 cells were
transiently transfected with Gal4DBD
or Gal4-NR2E3LBD expression plas-
mids. Transcriptional activity was
measured for the different luciferase
Gal4-reporter genes. A: Luciferase
activity in the presence of an in-
creasing amont of GAL-NR2E3LBD.
B: Luciferase acitity in the presence
of an increasing amount of GAL-
RARαLBD. C: Luciferase activity in
the presence of an increasing
amount of GAL-RARαLBD in the
presence of its ligand RA. Normal-
ized values are expressed as relative
luciferase activity.
596alone did not significantly inhibit the expression of luciferase
at 10 and 30 ng and was inhibitory only for the highest amount
of expression vector used (100 ng) with the SV40 promoter.
The activity was similar to that obtained with another nuclear
receptor, RARα, tested under the same conditions, and in ab-
sence of its ligand (Figure 1B). This inhibition was reverted
in presence of RAR ligand, the all-trans retinoic acid (Figure
1C).
Mutational analysis of NR2E3LBD:  To examine the func-
tional consequences of NR2E3 mutations described in ESCS,
we introduced six mutations found in ESCS (E121K, W234S,
R309G, R311Q, R385P, and M407K) and two artificially de-
signed mutations (R385L and αH12) into the Gal4-chimeric
receptor by site-directed mutagenesis. Most mutations exam-
ined are localized in the LBD, between positions 163 and 410,
of the human NR2E3 protein [7]. These Gal4-NR2E3LBD mu-
tant constructs were transfected into COS-1 cells and tested
for their ability to repress transcription from a Gal4 respon-
sive element fused to the β-globin minimal promoter (Figure
2A). Four out of six of the ESCS mutations (E121K, W234S,
R309G and R311Q) had slightly reduced inhibitory activity
as compared to wild-type. For these mutants, there was no
correlation between the NR2E3LBD transcriptional inhibition
activity and the ESCS phenotype.
As described previously, and confirmed here in another
cell line, the deletion of mutant H12 (N397Stop) results in the
total absence of transcriptional repression [14]. This is in agree-
ment with others studies where deletion of helix H12 enhances
repression and co-repressor binding, although several nuclear
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Figure 2. Transcriptional effect of NR2E3 mutations on Gal4 chi-
meric receptor.  A: COS-1 cells were transiently transfected with
100 ng of Gal4-NR2E3LBD wild-type and mutant expression plas-
mids. Transcriptional activity of a Gal4 responsive reporter gene was
measured. B: HeLa cells were transiently transfected with 100 ng of
Gal4-NR2E3LBD wild-type and mutant expression plasmids, and tran-
scriptional activity of a Gal4 responsive reporter gene was measured.
Normalized values are expressed as relative luciferase activity. C:
Expression of Gal4-NR2E3LBD wild-type and mutants in COS-1 trans-
fected cells. D: Electrophoretic mobility shift assay of Gal4 full-
length, wild-type (WT), and R385P mutated Gal4-NR2E3LBD using a
Gal4 probe. Bound indicates the different shifted bands, and free
denotes unbound probe.
Figure 3. Transcriptional effect of NR2E3 mutations on full-length
receptor.  A: COS-1 cells were transiently transfected with 100 ng of
NR2E3 wild-type and mutant expression plasmids, and transcrip-
tional activity of a NR2E3 responsive reporter gene was measured.
Normalized values are expressed as relative luciferase activity. B:
Expression of NR2E3 wild-type and mutants in COS-1 transfected
cells. C: Electrophoretic mobility shift assay of full-length wild-type
(WT) and mutated NR2E3 using a Kni x2 probe [6]. Bound indicates
shifted bands, and free denotes unbound probe.
597receptors lacking helix H12 act as transcriptional repressor
[30-32].
The ESCS mutation M407K corresponds to a position in
the helix H12 of nuclear receptors known to modulate the affin-
ity of the LBD to co-regulators. Again, and as seen by others,
the M407K NR2E3 mutant protein is not able to mediate tran-
scriptional repression [14].
The ESCS R385P mutation also results in loss of inhibi-
tion. This mutant is not localized within the helix H12, and
the loss of transcriptional inhibitory property must result from
a distinct mechanism. In order to test the possibility of a con-
formational constraint that might be created by the proline
residue, we designed the artificial R385L mutant with an argi-
nine residue replaced by a leucine residue. The R385L mutant
has an inhibitory activity slightly weaker than of the wild-
type NR2E3 and similar to that of four ESCS mutants.
Mutational analysis was also performed in HeLa cells
using Gal4 chimeric receptors and Gal4 responsive reporters
(Figure 2B). The six examined ESCS mutations presented simi-
lar behavior in HeLa and COS-1 cells; four of them (E121K,
W234S, R309G, and R311Q) retained a slightly reduced in-
hibitory activity, while R385P and M407K mutants were not
able to mediate transcriptional inhibition in HeLa cells. Only
the R385L artificial mutant has different behavior in the two
cell lines. It lost its repressive activity in COS-1 but remained
active in HeLa cells. The αH12 mutant displayed similar ac-
tivity in both cell lines.
In order to check that the lack of transcriptional inhibi-
tion was not the result of a difference in protein stability in
COS-1 cells, we performed Western blotting analysis (Figure
2C). The mutant fusion proteins were confirmed to be ex-
pressed at similar levels. The R385P mutant, which lacks the
inhibitory activity, was even expressed at a slightly higher level
than the wild-type construct. The loss of activity of the R385P
mutant could also theoretically result from misfolding of the
protein, and the resulting inability of this mutant to bind the
Gal4 responsive element. To study this hypothesis, nuclear
extracts from COS-1 transfected cells were prepared and used
in gel mobility assays in conjunction with oligonucleotides
corresponding to the Gal4 binding site (Figure 2D). Gal4 pro-
tein, used as a positive control, gave a shift in agreement with
its molecular weight (lane 4 and 5). Wild-type Gal4-NR2E3LBD
displayed two bands shifted in mobility (lanes 6 and 7) that
were also observed when the R385P mutant protein extract
was used (lanes 8 and 9). This provides the evidence that R385P
mutation has no effect on the conformation of the heterolo-
gous DNA binding domain.
Mutational analysis of full-length NR2E3:  Functional
consequences of NR2E3 mutations were also examined in full-
length protein. Four mutations found in ESCS (W234S,
R311Q, R385P, and M407K) were introduced into HA-tagged
full-length NR2E3 by site directed mutagenesis. These mu-
tated NR2E3 constructs were transfected into COS-1 cells and
tested for their ability to repress transcription from a NR2E3
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Figure 4. Expression of Gal4-NR2E3LBD.  A
and B mutant proteins after transfection into
COS-1 cells. The bottom panels represents
β-actin loading controls. A: Western blotting
against the GAL4-NR2E3 fusion proteins.
B:L Western blotting against the
hemaglutinin antigene (HA) tagged NR2E3
proteins.
598responsive element fused to the thymidine kinase minimal
promoter (Figure 3A) [7,14]. Two out of four of the mutations
(W234S and R311Q) had slightly reduced inhibitory activity
as compared to wild-type, while R385P and M407K mutants
lost most of their repressive activity.
To check for the stability of NR2E3 mutant proteins, we
analyzed COS-1 transfected cells by Western blotting. All the
full-length receptors, mutant or wild-type, were expressed at
similar level and had the expected electrophoretic mobility
(Figure 3B and Figure 4). As no natural DNA response ele-
ment has been identified for NR2E3, we used Kni 2X2, a
dimeric response element, which NR2E3 is able to bind [6,14].
Dimerization of several nuclear receptors has been shown to
be dependant upon LBD, indicating that LBD-localized mu-
tations could affect DNA binding ability. Nuclear extracts from
COS-1 transfected were analyzed by gel-shift mobility with
oligonucleotides corresponding to Kni X2 response element
[6] in order to check for the DNA binding of the different
NR2E3 proteins; mutant and wild-type (Figure 3C). All the
mutated full-length proteins displayed a band (lanes 6, 6', 8,
and 8') that was also observed with the wild-type full-length
protein (lanes 4 and 4'). This provides evidence that NR2E3
dimerization ability was not affected by these ESCS muta-
tions.
In order to test the possibility that NR2E3 is behaving
differently on inactivated and activated promoters, we tested
the four mutants for their ability to repress transcription driven
by Gal4 activation (Figure 5). The activation by Gal4 is re-
sulting from a cryptic Gal4 binding Element beside the NR2E3
responsive element in the reporter construct used [14]. Acti-
vation (two-folds) was observed in the presence of Gal4 pro-
tein. This activation was repressed by wild-type NR2E3. The
ESCS mutants have similar inhibitory properties toward this
Gal4-mediated transcriptional activity.
DISCUSSION
 The transcriptional inhibitory property of NR2E3 was also
reported in other cell types, such as the human embryonic kid-
ney (HEK) cells HEK 293, the kidney cells CV-1, and more
important the retinal pigmented epithelium (RPE) cells RPE-
J [14,22]. This inhibition was also observed when NR2E3 was
tested as a full-length protein on a selected DNA binding ele-
ment [14]. We have observed that the inhibition mediated by
NR2E3 resembles that of unliganded RARα. This suggests
the following: (1) that the inhibitory function of NR2E3 re-
sults from interactions of the LBD with co-repressors; (2) that
only a conformational change, may be induced by binding to
a ligand not present in these cells; (3) the exchange of co-
repressors to co-activators could results in transcriptional ac-
tivation [27]. Candidate ligands, as the all-trans and 9-cis
retinoic acid and the 11-cis retinaldehyde, have been previ-
ously excluded [22]. Nevertheless, the 13-cis retinoic acid was
recently reported as an NR2E3 agonist using a transcriptional
activation assay [28].
We have demonstrated here that some of the NR2E3 mu-
tants that cause ESCS disease are not defective in transcrip-
tional inhibitory activity. Four mutant proteins (E121K,
W234S, R309G, and R311Q) retain transcriptional repression
when tested as Gal4-fusion. Two of these mutants (W234S
and R311Q) that tested as full length on the identified NR2E3
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Figure 5. Repression of Gal4 activated promoter by NR2E3 wild-
type and mutant full-length proteins.  COS-1 cells were transfected
with various combinations of Gal4 (50 ng) and NR2E3 wild-type
and mutant (100 ng) expression plasmids. Transcriptional activity of
a NR2E3 responsive reporter gene was measured. Normalized val-
ues are expressed as relative luciferase activity.
Figure 6. Molecular model of NR2E3LBD.  Homology modeling of
the NR2E3LBD based on the RARLBD crystal structure. Highlighted
are several residues that mutated in enhanced S-cone syndrome. The
residue R385, shown in green, was predicted to localize in the ligand
hydrophobic pocket. Mutation of W234, shown in red, was predicted
to modify the ligand pocket conformation.
599responsive element are also fully capable of repressive func-
tion. The activation by Gal4 is resulting from a cryptic Gal4
binding Element beside the NR2E3 responsive element in the
reporter construct used (M407K and R385P). This absence of
correlation was also observed for Gal4 activated transcriptional
activation (Figure 5). A molecular model of NR2E3LBD was
established from the RARLBD crystal structure (Figure 6) [33].
The importance of position of M407K in the α-helix H12 of
nuclear receptors that interacts with co-regulators [30] is sug-
gested by the loss of repressive activity of the artificial mu-
tant with a deletion of that helix (DH12). The position of the
R385P mutation within a predicted hydrophobic pocket in a
structural model of the LBD of NR2E3 might suggest the re-
quirement of that residue in the interaction with a putative
activating ligand [28]. It is unclear why the artificial mutant
R385L retains transcriptional repression in COS-1 but not in
HeLa cells.
The work presented here demonstrates that there is no
correlation between the transcriptional inhibition mediated,
in vitro, by the ligand binding domain of NR2E3 and the phe-
notype of ESCS. The difference between the ESCS mutants
observed is not the result of differential interactions with pro-
tein partners such as the nuclear receptor NR1D1 or the
homeoprotein Crx reported to involve the DBD of NR2E3
[15,23].
There is an ongoing debate about the mechanisms lead-
ing to excess of S-cones in ESCS. The models currently dis-
cussed involved the inhibition of S-cone specific genes by
NR2E3 with [15,23,24] or without activation of rod-specific
genes [14]. The absence of rod function in ESCS [3,4] argues
for the involvement of NR2E3 in regulating rod-specific genes,
while the absence of perturbation of rod-specific expression
in the rd7 retina [14] indicates that in the absence of NR2E3,
rod-specific genes are expressed at a normal level.
While our results do not address the mechanisms behind
the lack of correlation between NR2E3 mutations and ESCS
the results point to the possible existence of transcriptional
activation properties of NR2E3 regulated by a yet to be iden-
tified ligand. ESCS mutants might all be defective in tran-
scriptional activation in addition for some of them to reduced
transcriptional inhibition. The recent identification of NR2E3
agonists is an element supporting this hypothesis.
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